P53 Attenuates Cancer Cell Migration and Invasion Through Repression of SDF-1/CXCL12 Expression in Stromal Fibroblasts
Overview
Affiliations
The p53 tumor suppressor acts as a major barrier against cancer. To a large extent, this is due to its ability to maintain genome stability and to eliminate cancer cells from the replicative pool through cell-autonomous mechanisms. However, in addition to its well-documented functions within the malignant cancer cell, p53 can also exert non-cell-autonomous effects that contribute to tumor suppression. We now report that p53 can suppress the production of the chemokine SDF-1 in cultured fibroblasts of both human and mouse origin. This is due to a p53-mediated down-regulation of SDF-1 mRNA, which can be exacerbated on activation of p53 by the drug Nutlin-3. SDF-1 promotes the migration and invasiveness of cells that express its cognate receptor CXCR4. Indeed, medium conditioned by p53-deficient fibroblasts induces cancer cells towards increased directional migration and invasiveness, which are largely reversed by CXCR4 antagonist peptides. Because SDF-1 produced by stromal fibroblasts plays an important role in cancer progression and metastasis, our findings suggest that the ability of p53 to suppress stromal SDF-1 production may be an important mechanism whereby it does its non-cell-autonomous tumor suppressor function.
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.
Song B, Yang P, Zhang S Cancer Commun (Lond). 2024; 44(3):297-360.
PMID: 38311377 PMC: 10958678. DOI: 10.1002/cac2.12520.
Cancer-associated fibroblasts: The chief architect in the tumor microenvironment.
Sarkar M, Nguyen T, Gundre E, Ogunlusi O, El-Sobky M, Giri B Front Cell Dev Biol. 2023; 11:1089068.
PMID: 36793444 PMC: 9923123. DOI: 10.3389/fcell.2023.1089068.
Tao Y, Li X, Zhang Y, He L, Lu Q, Wang Y Front Genet. 2022; 13:1057302.
PMID: 36568387 PMC: 9780475. DOI: 10.3389/fgene.2022.1057302.
Dual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives.
Toledo B, Picon-Ruiz M, Marchal J, Peran M Int J Mol Sci. 2022; 23(24).
PMID: 36555218 PMC: 9778751. DOI: 10.3390/ijms232415576.
Weigel C, Maczis M, Palladino E, Green C, Maceyka M, Guo C Cancer Res. 2022; 83(4):553-567.
PMID: 36541910 PMC: 9931683. DOI: 10.1158/0008-5472.CAN-22-1638.